Skip to main content
Back
FLGT logo

Fulgent Genetics, Inc.

Data quality: 100%
FLGT
NASDAQ Healthcare Medical - Diagnostics & Research
$16.34
▲ $0.01 (0.06%)
Mkt Cap: 510.31M
Day Range
$16.10 $16.44
52-Week Range
$13.46 $31.04
Volume
735,783
50D / 200D Avg
$22.12 / $22.79
Prev Close
$16.33

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -8.4 0.4
P/B 0.5 2.9
ROE % -5.4 3.9
Net Margin % -18.8 3.8
Rev Growth 5Y % -24.5 10.0
D/E 0.0 0.2

Analyst Price Target

Hold
$36.00 +120.3%
Forward EPS
-$1.41
Est. Revenue
350 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2028 -$1.44
-$1.46 – -$1.42
430 M 1
FY2027 -$1.48
-$1.71 – -$1.26
390 M 2
FY2026 -$1.41
-$1.51 – -$1.30
350 M 2

Key Takeaways

Revenue declined -24.49% annually over 5 years
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -124.21M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 38.32%
Capital efficient — spends only 7.00% of revenue on capex

Growth

Revenue Growth (5Y)
-24.49%
Revenue (1Y)13.83%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-5.39%
ROIC-6.14%
Net Margin-18.75%
Op. Margin-28.23%

Safety

Debt / Equity
0.00
Current Ratio6.48
Interest Coverage-1214.61

Valuation

P/E Ratio
-8.43
P/B Ratio0.46
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.83% Revenue Growth (3Y) 5.63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -24.49% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 322.67M Net Income (TTM) -60.51M
ROE -5.39% ROA -4.99%
Gross Margin 40.56% Operating Margin -28.23%
Net Margin -18.75% Free Cash Flow (TTM) -124.21M
ROIC -6.14% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 6.48
Interest Coverage -1214.61 Dividend Yield 0.00%
Valuation
P/E Ratio -8.43 P/B Ratio 0.46
P/S Ratio 1.58 PEG Ratio -0.34
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 510.31M Enterprise Value 460.59M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 322.67M 283.47M 289.21M 618.97M 992.58M
Net Income -60.51M -42.71M -167.83M 143.40M 507.36M
EPS (Diluted) -1.97 -1.41 -5.63 4.63 16.26
Gross Profit 130.88M 107.22M 104.46M 366.90M 777.05M
Operating Income -91.10M -73.92M -195.53M 178.53M 675.95M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.21B 1.22B 1.24B 1.39B 1.28B
Total Liabilities 106.81M 90.81M 102.04M 116.18M 112.84M
Shareholders' Equity 1.11B 1.13B 1.14B 1.27B 1.16B
Total Debt 476,000.0 8.47M 15.25M 38.94M 21.28M
Cash & Equivalents 50.19M 55.14M 97.47M 79.51M 164.89M
Current Assets 550.49M 353.57M 507.85M 627.87M 611.96M
Current Liabilities 84.97M 72.90M 73.02M 88.11M 105.31M